Renal vascular effects of cytokines

Blood Purification

Volumn 15, Issue 4-6, 1997, Pages 262-272

  Mariano, F ^a   Bussolati, B ^a   Piccolia, G ^a   Camussi, G ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; KIDNEY BLOOD VESSEL; PRIORITY JOURNAL;

ANIMALS; CYTOKINES; HUMANS; RENAL CIRCULATION;

EID: 0030732859     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000170344     Document Type: Article

References (126)

1. The ACCP/SCCM Consensus Conference Committee, Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992.101: 1644-1655.
2. Billiau A. Vandekerckhove F: Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 1991;21:559-573.
3. Van Deventer SJH. Buller HR. ten Cate JW. Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokines release and coagulation, fibrinolytic and complement pathways. Blood 1990;76:2520-2526.
4. Pober JS. Cotran RS: Cytokine and endothelial cell biology. Physiol Rev 1990:70:427-452.
5. Wedmore CV. Williams TJ: Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 1981:289:646-650.
6. Fantone JA, Ward PA: Role of oxygen derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol 1982:107:397- 418.
7. Camussi G. Bussolino F. Salvidio G. Baglioni C: Tumor necrosis factor/ca-chcctin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthetize and release platelet-activating factor. J Exp Med 1987; 166:1390- 1414.
8. Ohlstein EH. Nichols AJ: Rabbit polymorphonuclear neutrophils elicit endothelium-dependent contraction in vascular smooth muscle. Circ Res 1989: 65:917-924.
9. Camussi G. Albano E. Tetta C. Bussolino F: The molecular action of tumor necrosis factor-alpha. Eur J Biochem 1991:202:3-14.
10. Beutler B. Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 1987:316:379-385.
11. Tracey KJ, Beutler B, Lowry SF, Mcr-rywheather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ III, Zentella A, Albert JD, Shires T, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 1986: 234:470-474.
12. Zanetti G. Heumann D. Gerain J. Kohler J. Abbcl P. Barras C. Lucas R. Glauser MP. Baumgartner JD: Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysac-charide. J Immunol 1992:148:1890-1897.
13. Cannon JG, Tompkins RG, Geltand JA, Michic HR, Stanford GG, Van-derme JW, Endrcs S, Lonneman G, Corsctti J, Chemow B: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990:161:79-84.
14. Martich Danner RL, Ceska M, Suffre-dini A: Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxins: The effect of antiinflammatory agents. J Exp Med 1991;173:1021-1024.
15. Michic HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988:318:1481-1486.
16. Hesse DG. Tracey KJ. Fong Y, Manogue KR, Palladino MA. Cerami A, Shieres GT, Lowry SF: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Ob-stet 1988:166:147-153.
17. Van Der Poll T. Bulcr HR. ten Cate H: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990: 322:1622-1627.
18. Smith JW II, Urba WJ, Curti BD, El-wood U, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, et al: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992;10:1141-1152.
19. Okusawa S, Gelland JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin I induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of ciclooxygcnase inhibition. J Clin Invest 1988:81: 1162-1172.
20. Snyder F: Chemical and biochemical aspects of platelet-activating factor: A novel class of acetylated ether-linked choline phospholipids. Med Res Rev 1985:5:107-118.
21. Ogata M, Malsumoto T, Koga I, Ta-kenaka I, Kamochi M, Sata T, Yoshida S-I, Shigematsu A: An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun 1993;61: 699-704.
22. Braquet P, Touqui L, Shell TY, Vargaf-lig BB: Perspectives in platelet-activating factor research. Pharmacol Rev 1987;39:97-145.
23. Doebbcr TW, Wu MS, Robbins JC, Choy BM, Chang MN, Shen TW: Platelet-activating factor involvement in endotoxin-induced hypotension in rats: Studies with PAF receptor antagonist kadsurenonc. Biochcm Biophvs Res Commun 1985:127:799-808.
24. Terashita ZY, Imura Y, Nishikawa S, Sumida S: Isplatelet-activatingfactora mediator of endotoxic shock Eur J Pharmacol 1985:109:257-261.
25. Wang J. Dunn J: Platelet-activating factor mediates endotoxin-induced acute renal failure insufficiency in rats. Am J Physiol 1987;253:F1283-F1289.
26. Kuipers B, van der Poll T. Levi M. van Deventer SJH. ten Cate H, Imai Y. Hack CE. ten Cate JW: Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzee. J Immunol 1994:152: 2438-2446.
27. Glauser MP, Zanetti G, Baumgartner JD, Cohen J: Septic shock: Pathogenesis. Lancet 1991:338:732-735.
28. Blick M. Sherwin SA. Rosemblum M. Guttcrman J: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987:476:2986- 2989.
29. Selby P. Hobbs S. Viner C, Jakson E. Jones A, Newell D. Calvert AH, McEl-wain T. Fearon K, Humprey J, Shiga T: Tumor necrosis factor in man: Clinical and biological observations. Br J Cancer 1987:56:803-808.
30. Tracey KJ, Beutler B. Lowry SF, Mer-ryweather J, Wolpe S. Milsarck IW. Hariri RJ. Fahey TJ III. Zenlclla A. Albert JD. Shires GT. Cerami A: Shock and tissue injury induced by recombinant human cachcctin. Science 1986: 234:470-474.
31. Rcmick DG, Kunkcl RG, Larrick JW, Kunkel SL: Acute in vitro effects of human recombinant tumor necrosis factor. Lab Invest 1987;56:583-590.
32. Gresscr I, Woodrow D, Moss J, Maury C, Tavernier J, Fiers W: Toxic effects of recombinant tumor necrosis factor in suckling mice. Am J Pathol 1987; 128:13-18.
33. Bcrtani T, Abbate M, Zoja C, Coma D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 1989:134:419-430.
34. Girardin E, Grau GE, Paunicr L, Le Coultre C: Early hemodynamic and renal effects of tumor necrosis factor alpha: Role of thromboxane. Circ Shock 1994;42:20-26.
35. Brennan DC, Yui MA, Wuthrich RP, Kelley VE: Tumor necrosis factor and IL-1 in New Zealand blackAvhite mice. J Immunol 1989;143:3470-3475.
36. Tomosugi NI, Cashman SJ, Hay H, Pu-sey CD, Evans DJ, Shaw A, Rees AJ: Modulation of antibody-mediated glomerular injury in vivo by bacterial lipo-polysaccharidc, tumor necrosis factor and IH. J Immunol 1989:142:3083-3090.
37. Diamond JR, Pesek I: Glomerular tumor necrosis factor and interleukin-1 during acute aminonucleoside nephrosis. An immunohistochemical study. Lab Invest 1991:64:21-28.
38. Boswell JM, Yui MA, Burt DW, Kelley VE: Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988;141:3050-3054.
39. Brennan DC. Yui MA. Wuthrich RP. Kelley VE: Tumor necrosis factor and IL-1 in New Zealand blackAvhite mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143:3470-3475.
40. Camussi G, Tetta C, Bussolino F. Tu-rcllo E, Brentjens J, Montrucchio G, Andres G: Effect of leukocyte stimulation on rabbit immune complex glomerulonephritis. Kidney Int 1990:38: 1047-1055.
41. Pan CG. Brcsnahan BA, Albrigtson C, Lianos EA: Mesangial cell immune injury': Synthesis, origin and role of tumor necrosis factor. J Am Soc Nephrol 1993:4:627.
42. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, lenaga K, Kon-do M: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991:40:1007-1012.
43. Nakamura T, Fukui M, Ebihara I, Osad S, Nagaoka I, Tomino Y, Koide H: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993:42:450-456.
44. Hruby ZW, Shirota K, Hothy S, Lowry RP: Antiserum against tumor necrosis factor alpha and a protease inhibitor reduce immune glomerular injury. Kidney Int 1991:40:43-51.
45. Fiedler VB. Loof I. Sander E. Voehrin-ger V. Galanos C. Foumeri MA: Monoclonal antibody to tumor necrosis factor alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 1992:120:574-588.
46. Lovett DH, Sterzel RB. Ryan JL, Atkins E: Production of an endogenous pyrogen by glomerular mesangial cells. J Immunol 1985:134:670-672.
47. Baud L, Oudinet JP, Bens M, Noe L, Peraldi MM, Rondeau E, Etienne J, Ardaillou R: Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccha-ridcs. Kidney Int 1989:35:1111-1118.
48. Pouqucray B, Philippe C, Herbelin A, Perez J, Ardaillou R, Baud L: Cytokine formation within ral glomeruli during experimental endotoxemia. J Am Soc Nephrol 1993:4:1783-1791.
49. Kita T, Tanaka N, Nagano T: The im-munocytochemical localization of tumor necrosis factor and leukotriene in the rat kidney after treatment with li-popolysaccharidc. Int J Exp Pathol 1993;74:471-479.
50. Xia Y, Feng L, Yoshimura T, Wilson CB: LPS-induccd MCP-I, IL-1 beta and TNF-alpha expression in isolated erythrocyte-perfused rat kidney. Am J Physiol 1993;264:F774-F780.
51. Vlassara H, Brownlee M. Manogue KR. Dinarello CA, Pasagian A: Ca-chectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 1988:240: 1546-1548.
52. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R: In situ production of TNF alpha, IL-1 beta and IL-2R in ANCA positive glomerulonephritis. Kidney Int 1993:43:682-692.
53. Lovett DH. Larsen A: Cell-cycle dependent interleukin-l gene expression by cultured glomerular mesangial cells. J Clin Invest 1988:82:1 15-122.
54. Abbott F, Tam FWK, Ryan JJ, Rees AJ: Human mesangial cells synthesize interleukin-1 alpha but not interleukin-Ibeta. interleukin 1 receptor antagonist or tumor necrosis factor. Nephrol Dial Transplant 1992;7:997-1001.
55. Jevnikar AM. Brennan DC. Singer GG. Heng JE. Maslinski W. Wulhrich RP. Glimcher LH. Rubin Kelley VE: Stimulated kidney tubular epithelial cells express membrane associated and secreted TNFalpha. Kidney Int 1991; 40:203-211.
56. Yard BA. Daha MR. Kooymans-Cou-thino M. Bruijn JA. Paape ME. Schra-ma E. Van Es LA. Van Der Woode FJ: IL-lalpha stimulated TNF-alpha production by cultured human proximal tubular epithelial cells. Kidney Int 1992;42:383-389.
57. Yard BA, Pancham RR. Paape ME. Van Es LA, Van Der Woode FJ: CsA, FK506. corticosteroids and rapamycin inhibit TNFalpha production by cultured PTEC. Kidnev Int 1993:44:352-358.
58. Dinarello CA: The biological properties of interleukin-1. Eur Cytokine Netw 1994:5:517-531.
59. Camussi G. Mariano F, Bianconc L, Montrucchio G, Vercellone A: Effect of cytokines on the cytoskeleton of resident glomerular cells. Kidney Int 1993; 43:(suppl 39):32-36.
60. Schlondorff D, Goldwasser P, Ncu-wirth R, Satriano A, Clay KL: Production of platelet activating factor in glomeruli and cultured glomerular mesangial cells. Am J Phvsiol 1986:250: FI 123-FI 127.
61. Radeke HH, Meier B, Toplcy N, Floge J, Liabcrmchl GG, Resch K: IL-lalpha and tumor necrosis factor alpha induce oxygen radical production in mesangial cells. Kidney Int 1990:37:767-775.
62. Marsden PA, Brenner BM: Transcriptional regulation of the endothclin-l gene by TNF-alpha. Am J Physiol 1992;262:C854-C861.
63. Savic V, Stefanovic V. Ardaillou N, Ardaillou R: Induction of ccto-5-nucleoti-dase of rat cultured mesangial cells by IL-lbeta and TNFalpha. Immunology 1990:70:321-326.
64. Topley N, Floege J, Wcsscl K, Hass R, Radeke HH, Kaever V, Resch K: Prostaglandin E2 production is synergisti-cally increased in cultured human glomerular mesangial cells by combinations of IL-1 and TNFalpha. J Immunol 1989:143:1989-1995.
65. Marsden PA. Ballermann BJ: Tumor necrosis factor-alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. J Exp Med 1990; 172:1843-1852.
66. Rosenberg SA. Lotze MT. Muul LM, Leitman S. Chang AE. Ettinghausen SE, Matory YL. Skibber JM. Shiloni E. Vctto JT, Scipp CA. Simpson CG. Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985:313:1485-1492.
67. Rosenberg SA. Lotze MT. Muul LM, Chang AE. Avis FP, Leitman S. Line-han WM, Robertson CN. Lee RL. Rubin JT. Seipp CA. Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interlcu-kin-2 alone. N Engl J Med 1987:316: 889-897.
68. Rosenberg SA, Lotze MT, Mule’ JJ: New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 1988:108:853-864.
69. Rosenberg SA, Lotze MT. Yang JC. Linchan WM, Seipp C. Calabra S. Karp SE. Sherry RM, Steinberg S. White DE: Combination therapy with interleukin-2 and alpha interferon for patients with advanced cancer. J Clin Oncol 1989:7:1863-1874.
70. Lotze MT: Interlcukin-2: Basic principles; in De Vita VT Jr. Heilman S. Rosenberg SA (eds). Biologic Therapy of Cancer. London. Lippincoti 1991. pp 123-141.
71. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Velio J, Seipp CA, Rosenberg SA: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986;58:2764-2772.
72. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fiuid mediated by the systemic administration of recombinant intcr-leukin-2. J Immunol 1986,137:1735-1742.
73. Belldegrun A. Webb DE. Austin HA. Steimberg SM. White DE. Linehan WM. Rosenberg SA: Effects of interleu-kin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987:106: 817-822.
74. Kozeny GA, Nicolas JD, Creekmore S, Sticklin L, Hano JE, Fisher RI: Effects of interleukin-2 immunotherapy on renal function. J Clin Oncol 1988:6: 1170-1176.
75. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wicmik PH: Acute renal dysfunction during interleukin-2 treatment: Suggestion of an intrinsic renal lesion. J Clin Oncol 1990:8:1839-1846.
76. Sosman JA, Kohler PC, Hank JA, Moore KH. Beckhofer R. Storer B. Sandcl PM: Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule and addition of indomethacin. J Natl Cancer Inst 1988;80:1451-1461.
77. Fortis C, Galli L. C'onsogno G. Citterio G. Matteucci P, Scaglictti U. Bucci E: Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1. E-Se-lectin) and of cytokine TNF-alpha increase during interleukin-2 therapy. Clin Immunol Immunopathol 1995:76: 142-147.
78. Landmann R. Keiiholz U, Scheiben-bogen C, Brockhaus M, Galalti H, Denz H, Bargetzi M, Ludwig C: Relationship between soluble tumor necrosis factor (TNF) receptors and TNFalpha during immunotherapy with inler-leukin-2 and/or interferon alpha. Cancer Immunol lmmunother 1994;38: 113-118.
79. Baars JW, Wolbink GJ, Hart MHL, Hack CE, Eerenburg-Belmcr AJ, Pine-do HM, Wagstal TJ: Release of inlerleu-kin-8 during intravenous bolus treatment with interleukin-2. Ann Oncol 1994;5:929-934.
80. Thompson JA, Benyunes MC, Bianco JA, Fcfer A; Treatment with pentoxi-phynine and ciprofloxacin reduces the toxicity of high dose interleukin-2 and lymphokine-activated cells. Semin Oncol 1993:20:46-51.
81. Mier JW, Vachino G, Klempner M, Aroson FR, Noring R, Smith S, Brandon EP, Laird W, Atkins MB: Inhibition of interleukin-2 induced tumor necrosis factor release by dexamethasone: Prevention of an acquired neutrophil chemotaxic defect and differential suppression of interleukin-2 associated side elTccts. Blood 1990:76:1933-1940.
82. Fraker DL. Langstein HN. Norton JA: Passive immunization against tumor necrosis factor partially abrogates interleukin-2 toxicity. J Exp Med 1989: 170:1015-1020.
83. Mcmoli B. De Nicola L. Libetta C. Scialo A, Pacchiano G, Romano P, Pal-micri G. Morabito A. Lauda R. Conte G. Andreucci VE: Intcrleukin-2-in-duccd renal dysfunction in cancer patients is reversed by low- dose dopamine infusion. Am J Kidney Dis 1995; 26:27-33.
84. Baars JW, Hack CE, Wagstal TJ, Eercn-burg-Belmer AJ, Wolbink GJ, Thijs LG, Strack van Schindel RJ, Van der Vail HL, Pinedo HM: The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant intcrlcu-kin-2. Br J Cancer 1992:65:96-101.
85. Rosenberg SA. Lotzc M. Yang JC. Ac-bersol PM. Linchan WM. Seipp CA. White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989:210:474-484.
86. Thijs LG, Hack CE, Strack van Schi-jendel RJM, Nuijens JH, Wolbkin GJ, Nauta J, Pinedo HM, Hack CE: Activation of complement system during immunotherapy with interleukin-2. Relation to the development of side effects. J Immunol 1990:144:2419-2424.
87. Hack CE, Wagstaff J, Strack van Schi-jendel RJM, Eerenburg-Belmer AJ, Pinedo HM, Thlis MG, Nuijens JH: Studies on the contact system of coagulation during therapy with high doses of recombinant interleukin-2: Implication for septic shock. Thromb Hacmosl 1991:65:497-504.
88. Baars J, Boer JP, Wagstaff J, Roem D, Eeremberg-Belmer AJ, Balmar AJM, Narita J, Pinedo HM, Hack CE: Inter-lcukin-2 induces activation of coagulation and fibrinolysis: Resemblance to the changes seen during experimental endotoxemia. Br J Haematol 1992:82: 295-301.
89. Bussolino F. Camussi G. Aglietta M. Braquet P. Bosia A. Pescarmona GP. Sanavio F. D'Urso M. Marchisio PC: Human endothelial cells are target for platelet-activating factor: Platelet-activating factor induces changes:n cyto-skeleton structures and promotes albumin diffusion across endothelial mono-layer. J Immunol 1987:139:2439- 2446.
90. Camussi G, Turello E, Bussolino F, Ba-glioni C: Tumor necrosis factor alters cytoskeletal organization and barrier function of endothelial cells. Ini Arch Allergy Appl Immunol 1991:96:84-91.
91. Brady HR, Spertini O, Jimenez W, Benner BM, Marsden PA, Tedder TF: Neutrophils, monocytes and lymphocytes bind to cytokine-activated kidney glomerular endothelial cells throught.-selectin in vitro. J Immunol 1992:149: 2437-2444.
92. Hibbs JB. Westenfelder C. Timor R. Vaurin Z. Kabliz C. Baranowski RL. Ward JH. Menlove RL. McMurry MP. Kushner JP. Samlowski WE: Evidence after cytokine-inducible nitric oxide synthesis from /.-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992;89:867-877.
93. Miles D, Thomsen L, Balkwill F, Tha-vasu P, Moncada S: Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with in-lerleukin-2. Eur J Clin Invest 1994:24: 287-290.
94. Kilboum RG. Belloni I: Endothelial production of nitrogen oxides in response to interferon-gamma in combination with tumor necrosis factor, interleukin-1. or endotoxin. J Natl Cancer Inst 1990;82:772-776.
95. Kilboum RG. Griffith OW: Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 1992:84:872-881.
96. Lau KS. Nakashima O. Aalund GR. Hogarth L. Ujiie K. Yuen J. Star RA: TNF-alpha and IFN-gantma induce expression of nitric oxide synthase in cultured rat medullary interstitial cells. Am J Physiol 1995:269:F212-F217.
97. Moncada S. Higgs EA: The Z.-arginine-nitric oxide pathway. N Engl J Med 1993:329:2002-2012.
98. Estrada C, Gomez C, Martin C, Moncada S, Gonzalez C: Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Bio-chem Biophys Res Commun 1992: 186:475-482.
99. Wada T, Yokoyamma H, Tomosugi T, Hisada Y, Ohta S, Nailo T, Ko-bayashi KI, Mukaida N, Matsushima K: Detection of urinary interleukin-8 in glomerular disease. Kidney Int 1994;46:455-460.
100. Jacobson SH, Hylandcr B, Wretlind B, Brauner A: lnterleukin-6 and interleukin-8 in serum and urine in patients with acute pyelonephritis in relation to bacterial-virulence associated traits and renal function. Nephron 1994:67:172-179.
101. Wu X, Wittwer AJ, Carr LS, Crippes BA, De Larco JE, Lefkowith JB: Cytokine-induced neutrophil chemoattractant mediates neutrophil influx in immune complex glomerulonephritis in rat. J Clin Invest 1994:94:337- 344.
102. Feng L, Xia Y, Yoshimura T, Wilson CB: Modulation of neutrophil influx in glomerulonephritis in the rat with antimacrophage inflammatory protein 2 (MIP-2)antiboby. JClin Invest 1995;95:1009-1017.
103. Brown Z, Stricter RM, Chensue SW, Ceska M, Lindlev I, Neild GH, Kun-kel SL, Westwick J: Cytokine-activated human mesangial cells generate the neutrophil chemoattractant. IL-8. Kidney Im 1991;40:86-90.
104. Abbott F, Ryan JJ, Ceska M. Matsushima K. Sarraf CE, Rees AJ: Interleukin-! beta stimulates human mesangial cells to synthesize and release intcrlcukin-6 and -8. Kidney Int 1991;40:597-605.
105. Philippe C, Fouqucrav B, Ardaillou N, Baud L: TNF alpha-induced expression of IL-8 in human glomerular epithelial cells (GEC): Potential signaling pathways. J Am Soc Nephrol 1994:5:728.
106. Schmouder RL, Stricter RM, Wiggins RG. Chensue SW. Kunkel SL: In vitro and in vivo intcrleukin-8 production in human renal cortical epithelia. Kidney Int 1992;41:191-198.
107. Park IS. Kiyomoto H. Bames JL. Woodruff K. Abboud HE: Glomerular monocyte infiltration in early streptozocin-induced diabetes is associated with increased expression of transforming growth factor and cellular fibronectin. J Am Soc Nephrol 1994:5:971.
108. Stahl RAK. Tliaiss F. Disscr M. Hclmch U. Hora K. SchlondorIT D: Increased expression of monocyte chcmoattratctant protein-1 in antithymocyte antibody induced glomerulonephritis. Kidney lilt 1993:44: 1036-1047.
109. Rovin BH. Rumancik M, Tan L, Dickerson J: Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994: 71:536-542.
110. Neugarten T. Feith GW. Assman KTM. Shan Z. Stanley ER. Schlon-dorff D: Role of macrophages and colony stimulating factor in murine antiglomerular basement membrane glomerulonephritis. J Am Soc Nephrol 1995:5:1903-1909.
111. Mai M, Geiger FI, Hilgers KF, Veel-ken R, Mann JFE, Daemmrich J, Luft FC: Early interstitial changes in hypertension-induced renal injury. Hypertension 1993:22:754-765.
112. Mai M, Fierlbeck W, Geiger H: Differential expression of MCP-1 and RANTES in experimental renovascular hypertension. J Am Soc Nephrol 1994:5:757.
113. Diamond JR, Kees-Folts D. Ding G, Frye J. Restrepo NC: Macrophages, monocyte chemoattractant peptide-1 and TGF beta in experimental hydronephrosis. Am J Physiol 1994,266: F926-F933.
114. Safirstein R, Megycsi J, Saggi SJ, Price PM, Poon M, Rollins BJ, Taub-man MB: Expression of cytokine-like genes JE and KC is increased during renal ischemia. Am J Physiol 1991: 261:F1095-F1101.
115. Grandaliano G. Valente AJ. Rozek MM. Abboud HE: Gamma interferon stimulates monocyte chemotactic protein (MCP- Din human mesangial cells. J Lab Clin Med 1994; 123:282-289.
116. Zoja C. Wang JM. Bettoni S. Sironi M. Renzi D. Chiaffarino F. Abboud HE. Van Damme J. Mantovani A. Rcmuzzi G. Rambaldi A: Interleukin-1 beta and TNF alpha induce gene expression and production of leukocyte chemotactic factors, colony stimulating factors and intcrkukin-6 in mesangial cells. Am J Pathol 1991: 138:991-1003.
117. Fouqueray B, Grandaliano G, Wenzel U, Bhandari B, Woodruff K, Val-ante AJ, Abboud HE: Cytokines and thrombin regulate MCP-1 gene expression in bovine glomerular endothelial cells. J Am Soc Nephrol 1994: 15:747.
118. Rovin BH, Yoshimura T, Tan L: Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol 1992;148:2148-2153.
119. Brown Z. Stricter RM. Neild GH. Thompson RC. Kunkel SL. Westwick J: IL-1 receptor antagonist inhibits monocyte chemotactic peptide-1 generation by human mesangial cells. Kidney I n’t 1992:42:95.
120. Hora K. Satriano JA. Santiago A. Mori T. Stanley ER, Shan Z, Schlon-dorff D: Receptors for IgCi complexes activate synthesis of monocyte chemoattractant peptide I and colony stimulating factor I. Proc Nall Acad Sci USA 1992:89:1745-1749.
121. Rovin BH, Tan LC: LDL stimulated mesangial fibronectin production and chemoattractant expression. Kidney Ini 1993;43:218-225.
122. Grande JP. Jones ML. Swenson CL. Killen PD. Warren JS: Lipopolysac-charide induces monocyte chemoattractant protein production by rat mesangial cells. J Lab Clin Med 1994: 124:112-117.
123. Grandaliano G, Valente AJ, Abboud HE: A novel biologic activity of thrombin: Stimulation of monocyte chemotactic protein production. J Exp Med 1994:179:1737-1741.
124. Thaiss F. Helmchen U. Zahner G. Haberstroh U. Radounikli N. Schoeppe W. Stahl RAK: RANTES mRNA expression in glomeruli isolated from rats with autologous nephrotoxic serum nephritis. J Am Soc Nephrol 1993:4:638.
125. McLean A: Regulation with RANTES. Lancet 1994:343:189-190.
126. Pattison J, Nelson PJ, Huie P, von Leuttichau I, Farshid G, Sibley RK, Krensky AM: RANTES chemokine expression in cell mediated transplant rejection of the kidney. Lancet 1994:343:209-211.